Best printers for Home

Best Mixer Grinder

Best wired Earphones

Best 43 Inch TV in India

Best Wi Fi Routers

Best Home Theatre in India

Smart Watch under 5000

Best Laptops for Education

Best Laptop for Students

After years of intensified focus on <keyword id="19897423" type="General" weightage="20" keywordseo="COVID-19" source="keywords">COVID-19</keyword>, <keyword id="19992404" type="General" weightage="100" keywordseo="Tuberculosis" source="keywords">tuberculosis</keyword> (TB) has once again emerged as the leading <keyword id="20564668" type="General" weightage="20" keywordseo="infectious-disease" source="keywords">infectious disease</keyword> killer worldwide. This resurgence is a sobering reminder that despite our pandemic response, TB has continued to claim lives, especially in low- and middle-income countries (LMICs), where resources are often stretched thin. According to the latest <keyword id="19896311" type="General" weightage="20" keywordseo="World-Health-Organization" source="keywords" meta.keywordsubtype="org" meta.entityname="World Health Organization" meta.hostid="261" meta.entityid="World Health Organization">World Health Organization</keyword> (<keyword id="19895006" type="General" weightage="20" keywordseo="WHO" source="keywords">WHO</keyword>) report, approximately 8.2 million people were diagnosed with TB in 2023, marking the highest number of cases recorded since global monitoring began in 1995. <h2><keyword id="19895063" type="General" weightage="20" keywordseo="India" source="keywords">India</keyword> and Indonesia</h2>The recent spike in TB cases is largely driven by increases in two countries — India and Indonesia. Together, they accounted for 45% of the global rebound in TB diagnoses between 2021 and 2023, underscoring their critical role in the worldwide fight against TB. Three other countries, the Philippines, Nigeria, and Pakistan, also made significant contributions, collectively accounting for another 32% of the increase. This means that more than three-quarters of the global resurgence in TB can be traced to these five countries alone. One key reason for these increases is the “backlog” effect created by COVID-19 disruptions. During the pandemic, healthcare systems in many countries, including India and Indonesia, had to shift focus to COVID-19, which delayed TB diagnosis and treatment. In 2023, as these countries ramped up recovery efforts, many previously undetected TB cases surfaced, creating an apparent spike in reported numbers. This trend highlights the importance of sustainable healthcare infrastructure capable of handling simultaneous health crises. <h2>Gaps in TB case detection</h2>Despite the daunting increase in TB cases, some countries have made notable progress in <keyword id="23741990" type="General" weightage="20" keywordseo="treatment-coverage" source="keywords">treatment coverage</keyword>. Among the 30 high-burden TB countries, those with the highest levels of treatment coverage in 2023 included Brazil, India, Mozambique, Papua New Guinea, Sierra Leone, Uganda, and Zambia, with coverage rates surpassing 80%. India’s <keyword id="21052657" type="General" weightage="20" keywordseo="national-tuberculosis-elimination-program" source="keywords">National Tuberculosis Elimination Program</keyword> (NTEP) has undoubtedly played a pivotal role in this, aiming to eradicate TB by 2025 — five years ahead of the global target. By focusing on expanded testing, improved diagnostic tools, and more accessible treatment options, India has achieved high treatment coverage levels despite the challenges. <div type="Article" hostid="261" msid="114732986" title="Air Quality Alert: Nearly 30% of asthma cases tied to fine particulate matter exposure from bad air" mstype="2" mssubtype="0"></div>However, a significant treatment gap remains. The difference between estimated TB incidence and actual diagnoses still affects millions, especially in countries with large populations like India, Indonesia, Pakistan, China, and Myanmar. These five nations together account for about 50% of the global gap in reported TB cases, with India alone responsible for 16% of the discrepancy. <h2>India’s unique position in the global TB fight</h2>As the nation with the largest share of global TB cases, India has a unique and critical responsibility in addressing the disease. The high TB burden in India is tied to several factors, including undernutrition, poverty, and limited access to healthcare in rural areas. Moreover, with 26% of all TB cases globally, India’s battle against TB will significantly impact the global fight. The government’s financial support for TB-affected households also aims to reduce the economic burden of treatment. However, challenges remain, especially with <keyword id="22004277" type="General" weightage="20" keywordseo="multidrug-resistant-TB" source="keywords">multidrug-resistant TB</keyword> (MDR/RR-TB). While treatment success rates for MDR/RR-TB have reached 68%, diagnosing and treating all drug-resistant cases is an ongoing challenge. In 2023, India’s coverage of preventive treatment for TB among people living with HIV and close contacts of TB patients also saw improvements, but underfunding continues to limit the full scope of TB elimination efforts. <h2>Global funding gaps</h2>Global funding shortages for <keyword id="21039793" type="General" weightage="20" keywordseo="TB-prevention" source="keywords">TB prevention</keyword> and treatment are a significant hindrance to progress. Only $5.7 billion of the targeted $22 billion in funding was met in 2023, and for LMICs — where nearly all of the TB burden lies — the available funding falls well short of their needs. The United States remains the largest bilateral donor, and contributions from the Global Fund to Fight AIDS, Tuberculosis, and Malaria are crucial. However, these funds are not enough to meet essential TB service requirements, leaving healthcare systems under-resourced. <div type="Article" hostid="261" msid="114646545" title="Doctors struggle to treat long Covid patients in India; researchers point to inadequate studies" mstype="2" mssubtype="0"></div>Even in 2022, only one-fifth of the $5 billion target for research funding was achieved, as per the report. This underfunding hampers the development of improved diagnostics, drugs, and vaccines, which are crucial to TB prevention and treatment. Moreover, many of the drivers of TB are related to social factors, such as undernutrition, smoking, alcohol use, and diabetes, making it imperative to address these root causes. For instance, almost half of the TB-affected households globally face what the WHO calls "catastrophic costs" in seeking treatment. This burden is particularly severe in India, where low-income families often forgo treatment due to financial constraints. As WHO’s Director-General Dr Tedros Adhanom Ghebreyesus puts it, "The fact that TB still kills and sickens so many people is an outrage, when we have the tools to prevent it, detect it, and treat it.” The WHO’s Global tuberculosis report 2024 can be accessed <a href="https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2024">here</a>.

Tuberculosis dethrones COVID-19 as world’s top infectious killer again; Half of all new cases from India, Indonesia

<keyword id="19895063" type="General" weightage="20" keywordseo="India" source="keywords">India</keyword> has reported its first confirmed case of <keyword id="20134986" type="General" weightage="20" keywordseo="Monkeypox" source="keywords">Monkeypox</keyword> (<keyword id="20965747" type="General" weightage="20" keywordseo="Mpox" source="keywords">Mpox</keyword>) caused by the highly transmissible <keyword id="22812233" type="General" weightage="20" keywordseo="Clade-1B" source="keywords">Clade 1B</keyword> strain, marking a significant moment in the country’s ongoing battle against the <keyword id="20542503" type="General" weightage="20" keywordseo="viral-disease" source="keywords">viral disease</keyword>. According to sources in the <keyword id="19896140" type="General" weightage="20" keywordseo="Health-Ministry" source="keywords" meta.keywordsubtype="org" meta.entityname="Health Ministry" meta.hostid="261" meta.entityid="Health Ministry">Health Ministry</keyword>, this case involves a patient from <keyword id="19896018" type="General" weightage="20" keywordseo="Kerala" source="keywords">Kerala</keyword> <keyword id="19895006" type="General" weightage="20" keywordseo="WHO" source="keywords">who</keyword> had recently returned from Dubai. The World Health Organization (WHO) had recently raised concerns about the spread of Mpox, classifying it as a disease of international concern, especially as new, more infectious strains emerge. While Mpox has appeared in India before, all prior cases were linked to the less deadly Clade II strain. <h2>A new, more <keyword id="22892041" type="General" weightage="20" keywordseo="transmissible-strain" source="keywords">transmissible strain</keyword></h2>The case in Kerala is the first in India involving Clade 1B, a variant known for its higher transmission rate and increased mortality compared to previous strains. A Health Ministry official confirmed that the patient is currently in stable condition and that rigorous contact tracing efforts are underway to prevent further spread. This response follows India’s earlier experience with Mpox, where over 30 cases were recorded between 2022 and 2024, predominantly from travellers returning from African nations where the disease remains endemic. <h2>Mpox symptoms and spread</h2>Mpox manifests through typical viral symptoms, including fever, headaches, and muscle pain, eventually leading to skin rashes or lesions. These rashes often emerge a few days after the fever and vary in appearance, sometimes resembling fluid-filled blisters that crust over and heal within a few weeks. However, while symptoms usually resolve without intervention, the disease can lead to serious complications and, in rare instances, death. Unlike COVID-19 or influenza, Mpox is not airborne. Its primary mode of transmission is through close physical contact, particularly skin-to-skin contact or exposure to contaminated materials, such as bedding or clothing. Sexual transmission is also a significant factor in the spread of the disease. Health experts stress the importance of maintaining strict hygiene practices and ensuring that caregivers use personal protective equipment when attending to infected individuals. <h2>Health Ministry's preparedness</h2>In light of this new development, the Indian government is taking preventive measures to contain the situation. Union Health Secretary Apurva Chandra has issued directives to states and Union Territories, urging them to ensure isolation facilities are readily available for suspected or confirmed cases. These measures also include ramping up resources such as trained healthcare personnel and medical supplies. While there is no immediate risk of a widespread outbreak, authorities are adopting a cautious approach to avoid any potential escalation. Recent cases, such as one involving a resident of Hisar, Haryana, demonstrate the country’s ongoing efforts to monitor, isolate, and treat Mpox cases effectively. (With inputs from agencies)

More transmissible, higher fatality rate: India records first case of fast-spreading Mpox strain Clade 1B in Kerala man

A week or two of cold and cough can make you conjure up some pretty odd conspiracy theories. The freshest one that I cooked up this week is that 'Big Tissue' wishes to keep everyone sick, and therefore they collaborate with 'The Scientists' to keep them from making a cure. After all, the world witnessed researchers demonstrate incredible and hasty success in combating <keyword id="19897423" type="General" weightage="20" keywordseo="COVID-19" source="keywords">COVID-19</keyword>, and yet, the <keyword id="20237676" type="General" weightage="100" keywordseo="common-cold" source="keywords">common cold</keyword> remains an seemingly elusive target. But far from being an actual conspiracy, there are several real reasons why we haven’t yet cracked the code to curing the cold, despite decades of research. So grab your tissues, folks, and let's get into them. <h2><keyword id="23387393" type="General" weightage="20" keywordseo="viral-diversity" source="keywords">Viral diversity</keyword></h2>One major hurdle in curing the common cold is the sheer diversity of viruses involved. Over 200 viruses can cause cold symptoms, with <keyword id="23387392" type="General" weightage="20" keywordseo="rhinoviruses" source="keywords">rhinoviruses</keyword> responsible for up to 75% of cases. Rhinoviruses alone consist of more than 160 known strains. This viral diversity makes it extremely difficult to develop a universal vaccine or treatment. Unlike SARS-CoV-2, which has one main spike protein target, cold viruses come in a dizzying array of structures and behaviours, requiring a vast array of medical solutions. In contrast, when COVID-19 emerged, researchers focused primarily on one virus and one major target — its spike protein. That focus allowed for the rapid development of <keyword id="19953288" type="General" weightage="20" keywordseo="vaccines" source="keywords">vaccines</keyword> using mRNA technology, like those from Pfizer and Moderna. For the common cold, a similar solution isn’t feasible due to the multiple viral families involved. <h2><keyword id="20862236" type="General" weightage="20" keywordseo="mutations" source="keywords">Mutations</keyword> and adaptations</h2>Another issue is how quickly cold viruses mutate. Rhinoviruses, for example, are known for their high mutation rates. This rapid evolution allows them to evade the immune system, which is why even if you’ve had a cold before, you're not immune to future infections from different strains. <div type="Article" hostid="261" msid="113757960" title="Healthcare in India faces massive strain as costs rise by 14% annually; most expenses paid out-of-pocket" mstype="2" mssubtype="0"></div>This rapid mutation is akin to how COVID-19 has evolved into variants, but with cold viruses, it happens on an even greater scale. Scientists fear that if they developed a vaccine, new strains would quickly render it ineffective, much like how seasonal flu vaccines must be reformulated annually. <h2>Mildness of the illness</h2>Ironically, one reason the common cold hasn’t been cured is because it’s too mild to warrant massive investment. Most people recover from a cold without medical intervention. While cold symptoms are annoying — runny nose, sore throat, cough — they rarely escalate into serious illness. As a result, pharmaceutical companies and governments have little financial incentive to pour billions into research for a disease that poses no significant threat to public health. COVID-19, on the other hand, caused severe illness and death on a global scale, spurring massive investment from both the public and private sectors. Governments and companies alike invested heavily in research and fast-tracked vaccines, which led to solutions much quicker than we’ve seen for colds. <h2>Complex, complex immune system</h2>The immune system’s response to cold viruses is also a significant factor. Studies have shown that repeated exposure to cold viruses over a lifetime results in limited immunity. For instance, research from Harvard points out that even though the body produces antibodies after a cold, the <keyword id="20082133" type="General" weightage="20" keywordseo="immune-response" source="keywords">immune response</keyword> isn't strong enough to prevent future infections from slightly different strains. This is in stark contrast to diseases like measles, where one infection can result in lifelong immunity. COVID-19 benefitted from its novelty. The immune system had never encountered SARS-CoV-2 before, making it easier to target with vaccines that produce a strong and specific immune response. Here’s an additional fun fact: because there are SO many different strains of common cold-causing viruses, research says that it is unlikely that you will be infected with the same strain of common cold twice throughout your life! <h2>Attempts to develop treatments</h2>There have been attempts to develop treatments for the common cold. Some researchers have targeted the way viruses enter and replicate in human cells. For example, a 2018 study explored inhibiting the protein that cold viruses use to replicate, showing some promise in early trials. However, most of these treatments are in the experimental phase, and none have been widely successful yet. <div type="Article" hostid="261" msid="113284254" title="Gastro problems could heighten Parkinson&amp;#39;s disease risk by 76%, study finds" mstype="2" mssubtype="0"></div>In recent years, attention has shifted towards using broad-spectrum antiviral drugs that can target multiple viruses at once, similar to how some antibiotics work against a range of bacteria. However, this approach has yet to yield a major breakthrough. The idea of a universal cure for the common cold remains distant, but advances in genetic research and vaccine technology offer some hope. For example, CRISPR technology may allow scientists to edit out the genetic components that cold viruses rely on to replicate. Additionally, the mRNA technology used for COVID-19 vaccines has opened new possibilities for antiviral treatments, although these applications are still in early stages. Research continues, but for now, humanity may have to continue battling sniffles and coughs the old-fashioned way: with rest, fluids, and time.

How did we manage to deal with COVID-19 so quickly, but the common cold still remains a persisting problem?

Everything is connected. Nature itself thrives on an intricate web of interdependence, with every element—including human beings—complexly intertwined. Now, this fundamental fact is being further reinforced by new findings on COVID-19. The <keyword id="8858345" type="General" weightage="20" keywordseo="SARS-CoV-2" source="Orion">SARS-CoV-2</keyword> virus initially jumped from animals to humans, triggering a pandemic on the global stage. As cases multiplied across populations worldwide, humans have ended up spilling the virus back into the wildlife, leading to new outbreaks among various animal species. Genetic analysis of <keyword id="6383885" type="General" weightage="20" keywordseo="wild-animals" source="Orion">wild animals</keyword> has revealed not only the presence of SARS-CoV-2, but also the emergence of unique <keyword id="22599311" type="General" weightage="20" keywordseo="viral-mutations" source="keywords">viral mutations</keyword>. These mutations show a close relationship to the variants circulating among humans, illustrating the ongoing exchange between our species and wildlife. <cmsannotation type="cmsannotation" annotationid="Nature’s COVID-19 cycle: From wildlife to humans and back again" comment="subhead" text="Nature’s COVID-19 cycle: From wildlife to humans and back again">Nature’s COVID-19 cycle: From wildlife to humans and back again</cmsannotation> The study by Virginia Tech involved analysing 798 nasal and oral swabs from animals trapped in the field or treated at wildlife rehabilitation centres across Virginia, US, along with 126 blood samples from six species. This research, recently published in Nature Communications, aimed to track the virus’s presence in animals from both urban and remote areas. The findings are revealing: the virus was detected in deer mice, Virginia opossums, raccoons, groundhogs, Eastern cottontail rabbits and Eastern red bats. Notably, one opossum exhibited viral mutations not previously reported, which could influence human health and immune responses. Exposure rates varied by species, ranging from 40% to 60%. The study also noted a peculiar finding: two mice at the same site on the same day carried identical viral variants, suggesting possible direct transmission between them, or from a common human source! The highest rates of virus exposure were observed in animals near hiking trails and high-traffic areas, indicating that human activity is a significant factor in the spread to wildlife. The exact transmission pathways remain unclear, with possibilities including wastewater or discarded food. However, researchers emphasise that while the virus is spreading to wildlife, there is no evidence of reverse transmission from animals to humans. <div type="Article" hostid="261" msid="112014490" title="Cows are now spreading bird flu to each other — here&amp;#39;s why that&amp;#39;s problematic for humans" mstype="2" mssubtype="0"></div>Carla Finkielstein, a professor of biological sciences, describes the virus' behaviour as akin to “a hitchhiker switching rides to a new, more suitable host”. With humans largely protected by vaccines, the virus—with the sole goal of spreading and surviving—is adapting and mutating to thrive in animal hosts. Although this study is limited to Virginia, the species affected are found throughout North America. This means the findings may also be applicable to other countries and continents to a certain extent. Moreover, this research doesn’t just highlight the novel mutations in SARS-CoV-2, but also underscores the broad host range of the virus. Therefore, researchers stress the urgent need for extensive surveillance to monitor the virus' impact on wildlife and its potential implications for vaccine development.

Humans are spilling the COVID-19 virus back into wildlife! Study finds widespread infection in backyard animals

New Delhi [India] March 30 (ANI): A total of 3016 new <keyword id="8869954" type="General" weightage="20" keywordseo="covid-cases" source="Orion">Covid cases</keyword> were recorded in the last 24 hours across the country with a daily positive rate of 2.73 per cent, a government release said on Thursday, adding that 15,784 doses of COVID vaccines were administered during the same period. According to the release, 1,10,522 tests were conducted in the last 24 hours, taking the total number of tests conducted so far to 92.14 crores. It stated further that a total of 1,396 recoveries were made from the virus in the last 24 hours, taking the total number of recoveries to 4,41,68,321. It stated that 220.65 cr total vaccine doses (95.20 cr Second Dose and 22.86 cr Precaution Dose) have been administered so far under Nationwide Vaccination Drive. Further, India's active caseload currently stands at 13,509 with a rate of 0.03 per cent per day and with a recovery rate currently standing at 98.78 per cent. It stated that the weekly positivity rate stands at 1.71 per cent. Meanwhile, Delhi Health Minister Saurabh Bhardwaj called an emergency meeting on Thursday afternoon after 300 fresh Covid-19 cases were recorded in the Capital on Wednesday. "Health Minister Saurabh Bhardwaj will hold a meeting with the officers and specialist doctors associated with the health department this afternoon," officials said. The Special Secretary, Health Department, Director of General Health Services, Nodal Officer for Oxygen and Testing and Medical Directors of several hospitals including Lok Nayak Jai Prakash Narayan (LNJP) will be present in the meeting. The country recorded new 2151 Covid cases between Tuesday and Wednesday with a daily positive rate of 1.51 per cent, an official statement said on Wednesday, adding that 11,336 doses of vaccines were administered in the last 24 hours. Meanwhile, Delhi recorded 300 fresh Covid-19 cases and two deaths on Wednesday, marking a sharp uptick in infections over the last 24 hours. According to a bulletin issued by the Delhi Health department on Wednesday, the capital registered two deaths from Covid over the last 24 hours. The Ministry of Health and Family Welfare issued revised guidelines for Covid-19 in the wake of the surge of cases in the past week across the country. "Antibiotics should not be used unless there is clinical suspicion of bacterial infection. The possibility of coinfection of COVID-19 with other endemic infections must be considered. Systemic corticosteroids are not indicated in mild disease," revised guidelines said. As per the revised Covid-19 guidelines, maintain "Physical distancing, indoor mask use, hand hygiene, Symptomatic management (hydration, antipyretics, antitussive) Monitor temperature and oxygen saturation (by applying a SpO probe to fingers) Stay in contact with the treating physician. "Seek immediate medical attention if difficulty breathing, High-grade fever/ severe cough, particularly if lasting for more than 5 days. A low threshold is to be kept for those with any of the high-risk features," guidelines discussed and prepared in January said. Additionally, in moderate or severe diseases at high risk of progression, the guidelines recommend, "Consider Remdesivir for up to 5 days (200 mg IV on day 1 followed by 100 mg IV OD for the next 4 days)". SEE ALSO: <a href="https://www.businessinsider.in/tech/mobile/news/moto-g13-vs-realme-c55-mobile-phones-comparison-of-price-specification-and-features/slidelist/99106985.cms">Moto G13 vs Realme C55 – price, specs, and features compared</a> <a href="https://www.businessinsider.in/tech/news/here-are-the-jobs-chatgpt-says-ai-can-take-from-humans/slidelist/99087522.cms">We asked ChatGPT about jobs that AI can take over from humans – This was its answer</a> <a href="https://www.businessinsider.in/business/startups/news/zomato-gold-swiggy-dineout-competitor-eazydiner-raises-40-crore/articleshow/99091065.cms">EazyDiner raises ₹40 crore from DMI Alternative Investment Fund</a>

India reports 3,016 new Covid-19 cases, daily positive rate at 2.7%

New York [US], April 5 (ANI): The <keyword id="10561122" type="General" weightage="20" keywordseo="bird-flu-pandemic" source="Orion">bird flu pandemic</keyword> with the potential to be "<keyword id="21202249" type="General" weightage="20" keywordseo="100-times-worse" source="Orion">100 times worse</keyword> than COVID" may be on the horizon after a rare human case was discovered in Texas, experts have warned, the New York Post reported on Thursday. The <keyword id="21202246" type="General" weightage="20" keywordseo="H5N1-avian-flu" source="keywords">H5N1 avian flu</keyword> has spread rapidly since a new strain was detected in 2020 affecting wild birds in every state, as well as in commercial poultry and backyard flocks. But the recent cases detected in mammals, with cattle herds across four states becoming infected and on Monday, federal health officials announced that a dairy worker in Texas caught the virus. "This virus [has been] on the top of the pandemic list for many, many years and probably decades," Suresh Kuchipudi, a <keyword id="95867" type="General" weightage="100" keywordseo="bird-flu" source="Orion">bird flu</keyword> researcher from Pittsburgh, said at a recent panel discussing the issue, the New York Post reported citing the Daily Mail. "And now we're getting dangerously close to this virus potentially causing a pandemic." He noted that the <keyword id="565908" type="General" weightage="20" keywordseo="H5N1-virus" source="Orion">H5N1 virus</keyword> has already been detected in species throughout the world and "has shown the ability to infect a range of mammalian hosts, including humans." "So therefore, in my view, I think this is a virus that has the greatest pandemic threat [that is] playing out in plain sight and globally present," Kuchipudi said. John Fulton, a pharmaceutical industry consultant for vaccines and the founder of Canada-based BioNiagara who organized the meeting, also expressed his concerns, the Mail reports, the New York Post reported. "This appears to be 100 times worse than COVID -- or it could be if it mutates and maintains its high case fatality rate," he said. "Once it's mutated to infect humans, we can only hope that the [fatality rate] drops." Around 52 per cent of humans who have contracted H5N1 since 2003 have died, according to the World Health Organization. For comparison, COVID currently kills less than 0.1% of those it infects -- though at the start of the pandemic, the fatality rate was around 20 per cent. Symptoms of the bird flu are similar to those of other flus, including cough, body aches and fever, the New York Post reported. Some people may not develop noticeable symptoms, but others can develop severe, life-threatening pneumonia. The dairy worker in Texas who was infected has reported "eye redness (consistent with conjunctivitis)" as their only symptom, the Centers for Disease Control and Prevention noted. "The patient was told to isolate and is being treated with an antiviral drug for [the] flu," the CDC said. The agency and "the whole US government is taking this situation very seriously," CDC Director Mandy Cohen told the Washington Post. She maintained that the virus does not pose much of a risk to the general public, noting that the dairy worker was in direct contact with infected cattle, and the US Department of Agriculture has said there are currently no changes that would make it more transmissible to humans. "While cases among humans in direct contact with infected animals are possible, this indicates that the current risk to the public remains low," the department said in a statement over the weekend. But the fact that the virus has been found in cattle could mean it is starting to mutate, Cohen told the Washington Post. "We had not seen avian flu in cattle prior to last week. That is new," she said. "It is a reservoir for [the] virus to circulate and potentially change." If the virus does mutate enough to infect humans, it could spread rapidly, the European Food Safety Authority warned on Wednesday, according to Fox News. "If avian A [H5N1] influenza viruses acquire the ability to spread efficiently among humans, large-scale transmission could occur due to the lack of immune defences against H5 viruses in humans," the Food Safety Authority said. To prevent any potential spread, the US is already testing components used to create a vaccine for the virus, and two candidate vaccine viruses appear to be well-matched to protect against H5N1, the Washington Post reports. White House press secretary Karine Jean-Pierre also said the Biden administration is monitoring the threat. "We take the health and safety of the American people seriously," she said at her briefing on Wednesday. "It is very important to this president. Our top priority is to keep communities healthy, safe and informed."

Scientists warn of bird flu pandemic that could be '100 times worse' than COVID after rare human case found in US

Ever since the virus reared its ugly head and briefly sent the world into despair, the coronavirus has remained a staple, albeit almost sidelined, part of the news cycle. Despite this, the topic has come to the forefront of controversy once again, with an extremely popular <keyword id="20040659" type="General" weightage="20" keywordseo="COVID-19-vaccine" source="keywords">COVID-19 vaccine</keyword> now under scrutiny. Considering that the world is still healing from the scars left behind by the coronavirus tragedy, it is imperative that we gauge the situation to avoid any unwarranted public paranoia. Let’s look at the facts behind the ongoing <keyword id="19910149" type="General" weightage="20" keywordseo="AstraZeneca" source="keywords" meta.keywordsubtype="org" meta.entityname="AstraZeneca" meta.hostid="261" meta.entityid="AstraZeneca">AstraZeneca</keyword> (or <keyword id="19960109" type="General" weightage="100" keywordseo="covishield" source="keywords">Covishield</keyword>, as it is known in India) vaccine controversy, and determine if there really is a cause for worry. <cmsannotation type="cmsannotation" annotationid="What happened?" comment="subhead" text="What happened?">What happened?</cmsannotation> Shortly after receiving the AstraZeneca COVID-19 vaccine in 2021, UK-based <keyword id="21472612" type="General" weightage="20" keywordseo="jamie-scott" source="keywords">Jamie Scott</keyword> experienced a harrowing ordeal. He developed a brain clot and severe bleeding, resulting in permanent brain injury. This condition, known as <keyword id="21475609" type="General" weightage="20" keywordseo="Thrombosis-with-Thrombocytopenia-Syndrome" source="keywords">Thrombosis with Thrombocytopenia Syndrome</keyword> (<keyword id="20218859" type="General" weightage="20" keywordseo="tts" source="keywords">TTS</keyword>), can lead to dangerously low blood clot and platelet levels, posing a grave risk to those affected. Jamie's struggles with memory loss, impaired vision, and diminished cognitive abilities compelled him to seek legal recourse against the pharmaceutical company in 2023. Jamie's legal representative contends that AstraZeneca minimized the potential risks linked to their vaccines. Moreover, reports indicate that over 50 vaccinated individuals experienced similar adverse conditions, with numerous cases resulting in fatalities or severe injuries. Despite these assertions, the pharmaceutical company refutes the allegations, stating that they do not acknowledge a causal relationship between the vaccine and Thrombosis with Thrombocytopenia Syndrome (TTS) on a generic level. However, a year of court wrangling later, legal documents submitted by AstraZeneca have now admitted that their vaccine can cause TTS in very rare cases, although the causal mechanism is still not well known. This revelation has led to renewed uproar against the vaccine’s side-effects. <cmsannotation type="cmsannotation" annotationid="Is there cause for worry?" comment="subhead" text="Is there cause for worry?">Is there cause for worry?</cmsannotation> In short words, not really. Links between the <keyword id="21483117" type="General" weightage="20" keywordseo="AstraZeneca-vaccine" source="keywords">AstraZeneca vaccine</keyword> and vaccine-induced immune TTS have been scientifically identified since early 2021, soon after the first COVID-19 vaccines had come out. However, it is so very rare — a few dozen reported cases among the millions administered — that even the World Health Organisation has deemed the vaccine “safe and effective” for all individuals aged 18 and above. Moreover, even influenza, H1N1 and rabies vaccines can cause TTS in very rare instances. Further, it is important to note that an infection with COVID-19 is itself a major cause for clot, heart attacks and strokes. Being vaccinated actually lowers these risks. There is also the fact that all vaccines or drugs carry potential side-effects, and these medical interventions are only cleared for release after determining that their benefits vastly outweigh any complications. Finally, the <keyword id="21483118" type="General" weightage="20" keywordseo="TTS-side-effects" source="keywords">TTS side-effects</keyword> — which include symptoms such as headaches, blurred vision, chest pain, leg swelling or tiny blood spots under the skin — manifest between 1-6 weeks of vaccination. Considering that most Indians received their Covishield jab a couple of years ago, there should be no reason to panic now. <cmsannotation type="cmsannotation" annotationid="Is it time to consider alternate vaccines?" comment="subhead" text="Is it time to consider alternate vaccines?">Is it time to consider alternate vaccines?</cmsannotation> There is no particular hard evidence that suggests the supremacy of one vaccine over another, considering that they all carry varying degrees of side-effects. That being said, <keyword id="9485939" type="General" weightage="20" keywordseo="covaxin" source="Orion">Covaxin</keyword> boasts a higher efficacy than Covishield, and has better research data among Indian subjects. However, it may also be important to know that the administration of the AstraZeneca vaccine has been discontinued in many countries, mainly due the aforementioned risk of blood clotting in certain age groups. Whatever the choice, the fact of the matter remains that these vaccines have saved millions since their introduction, and it is pertinent that we continue taking them diligently, unless any premier health authorities recommend otherwise.

Should you be worried about the potential side-effects of the Covishield vaccine?

<ul class="summary-list"><li>Traders are increasingly pinning their hopes on an emergency Fed rate cut.</li><li>They currently see a 60% chance that central bankers will cut rates by 25 basis points within the next week.</li></ul>Wall Street has been so suddenly gripped by fears of recession that talks of an emergency rate cut are gathering steam.Traders are pricing in a 60% chance the Fed could issue an emergency 25 basis-point rate cut in the next week, <a target="_blank" class="" href="https://www.bnnbloomberg.ca/investing/2024/08/04/bond-traders-bet-big-on-the-fed-launching-into-rescue-mode/">Bloomberg</a> reported.That's evidenced by an extreme rally in the US bond market, with US Treasury yields — which are tied to interest rate expectations — dropping to their lowest level in a year. The yield on the 2-year Treasury note plunged as much as 16 basis points on Monday, while the yield on the <a target="_blank" class="" href="https://markets.businessinsider.com/rates/u-s--rates-10-years?miRedirects=1">10-year Treasury note</a> dropped as much as 10 basis points.Investors in risk-off mode after an unexpectedly weak jobs report on Friday. Payroll growth slowed more than expected last month, while the unemployment rate surged. That <a target="_blank" class="" href="https://www.businessinsider.com/sahm-rule-recession-outlook-indicator-triggered-unemployment-rate-jobs-report-2024-8">triggered the Sahm Rule</a>, a highly accurate recession indicator that flashes when the three-month moving average of the unemployment rate surpasses a key threshold.That's led more investors to wonder whether the Fed made a mistake in waiting over 28 months from their first rate hike to ease monetary policy — with some urging central bankers to take drastic measures in the coming weeks.Wharton professor Jeremy Siegel pressed the Fed to issue an emergency 75 basis-point rate cut, followed by another 75 basis-point rate cut at their September policy meeting. Otherwise, markets risk responding poorly, since interest rates should be about 175 basis points lower from where they are now, he told <a target="_blank" class="" href="https://www.cnbc.com/2024/08/05/whartons-jeremy-siegel-says-fed-needs-to-make-an-emergency-rate-cut.html">CNBC</a> in an interview on Monday."How much have we moved the fed funds rate? Zero," he said. "That makes absolutely no sense whatsoever.""If they are going to be as slow on the way down as they were on the way up, which by the way was the first policy error in 50 years, then we're not in for a good time with this economy," Siegel later added.Nobel Laureate Paul Krugman also said he saw a case for an emergency rate cut, pointing to the <a target="_blank" href="https://markets.businessinsider.com/news/stocks/stock-market-today-nasdaq-enters-correction-territory-jobs-report-panic-2024-8">panicked selloff in stocks</a>."I wasn't calling for an inter-meeting cut, because that might signal panic. But since we may be seeing a panic anyway, that argument loses its force. Real case for an emergency cut soon," he said in a <a target="_blank" href="https://x.com/paulkrugman/status/1820426175031673269">post</a> on X.The Fed typically only implements interest rate changes during its scheduled policy meetings. But it has issued early rate moves during times of extreme volatility, such as during the <a target="_blank" class="" href="https://www.businessinsider.com/fed-interest-rate-cut-zero-bond-holdings-coronavirus-pandemic-economy-2020-3">COVID-19 pandemic</a>, or the dot-com stock crash.Markets are also ramping up their bets for steeper-than-expected rate cuts through the end of the year. Investors are pricing in a 92% chance the Fed will cut rates by 100 basis points or more by the end of the year, according to the <a target="_blank" class="" href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">CME FedWatch tool</a>, up from 0.2% odds priced in a week ago."We now expect faster cuts because the funds rate looks more clearly inappropriately high," Goldman Sachs economists said in a note on Monday, raising the odds of an incoming recession to 25%. "The Fed looks behind, having worried too much about inflation for too long and held steady in July; and the rationale for cutting now includes the more urgent priority of supporting the economy."

An emergency rate cut in the next week is looking more likely

<ul class="summary-list"><li>This post originally appeared in the Insider Today newsletter.</li></ul>Good morning. Memorials are being <a target="_blank" rel="noopener noreferrer" href="https://www.businessinsider.com/middle-east-israel-iran-lebanon-high-alert-october-anniversary-attacks-2024-10">held across Israel today</a> to mark the one year anniversary of the October 7 terror attacks.In today's newsletter, earnings season is upon us. <a target="_blank" href="https://markets.businessinsider.com/news/stocks/stock-market-q3-earnings-preview-investors-themes-ai-interest-rates-2024-10">Here's what to look out for</a>.What's on deck:<ul><li>Markets: The 49 fintech startups worth keeping an eye on, <a target="_blank" href="https://www.businessinsider.com/49-most-promising-fintech-startups-according-top-vc-investors-2024">according to VCs</a>.</li><li>Tech: Amazon's Prime Day kicks off tomorrow, and there are some deals on <a target="_blank" href="https://www.businessinsider.com/amazon-october-prime-day-sale-includes-unusual-holiday-items-2024-10">surprising items</a>.</li><li>Business: Activist investor Starboard has informed Pfizer it has <a target="_blank" rel="noopener" href="https://www.businessinsider.com/starboard-activist-significant-stake-in-drugmaker-pfizer-2024-10">taken a significant stake</a>.</li></ul>But first, let's double-click on that for a second.If this was forwarded to you, <a target="_blank" href="https://www.businessinsider.com/subscription/newsletter/insider-today">sign up here.</a><h3 id="7fa5f018-5b05-4a37-a8dc-d3f89138bcb3">The big story</h3><h2 id="5fd547b9-ec52-41fc-8e08-4f4b27dd8097">EBITDA for everybody</h2><div type="image" title="trader at desk" height="1500" width="3000" msid="114018838" hostid="261" sizebytes="186350"></div>It's beginning to look a lot like earnings season.The numbers are being crunched and talking points prepared as companies get ready to report their financials and discuss expectations for the final stretch of 2024.Business Insider's Matthew Fox has a rundown of the <a target="_blank" href="https://markets.businessinsider.com/news/stocks/stock-market-q3-earnings-preview-investors-themes-ai-interest-rates-2024-10">biggest themes investors are watching this earnings season</a>.This crop of earnings is particularly important. It follows the first interest-rate cut in more than four years as the economy is on the cusp of nailing its soft landing. Meanwhile, the S&amp;P 500 gained 5% in the third quarter while trading near record highs.That translates into big expectations from investors, with Wall Street analysts looking for the S&amp;P 500 to see year-over-year earnings growth of 4.6%.Luckily for us, we'll get a sense of where things are headed early on. Big banks begin reporting at the end of the week, with JPMorgan and Wells Fargo kicking things off. The sector can act as a proxy for the wider market, with its insight into the health of consumers and corporations.But the true test will come in a few weeks when Big Tech reports, offering another update on how its massive bets on AI are paying off (or not at all).<div type="image" title="Jerome Powell Photo illustration" height="600" width="1200" msid="114018843" hostid="261" sizebytes="29880"></div>We've already got one indication companies are in good shape: <a target="_blank" href="https://www.businessinsider.com/september-jobs-report-unemployment-rate-nonfarm-payroll-growth-federal-reserve-2024-10">Friday's blockbuster jobs report</a>.The US economy added 254,000 jobs in September (the consensus forecast was 147,000), and unemployment dropped to 4.1% (estimates were it would stay at 4.2%).Considering the jobs market is the top priority of the Fed now that inflation is under control, that's good news … sort of.If you were banking on another jumbo rate cut next month, <a target="_blank" href="https://www.businessinsider.com/september-jobs-report-fed-rate-cut-outlook-november-labor-market-2024-10">those hopes have been dashed</a>. (One firm thinks there's still a chance, pointing to a low response rate on the survey that <a target="_blank" href="https://www.businessinsider.com/september-jobs-payroll-report-fed-rate-cut-outlook-labor-market-2024-10">could lead to a revision down</a>.)Philipp Carlsson-Szlezak, Boston Consulting Group's global chief economist, told me he expects the Fed to stick with the standard 25-basis-point cuts.But another blowout report — 250,000 jobs added and at least 4% wage growth — could lead the Fed to reconsider its easing policy."Just wait and see how this is going. This is so strong. There's no need to cut. We need to restrain the economy a little. Let's just pull back on the pace," he said.<h3 id="77f31a4c-8462-4e3d-a71f-838cb79493fb">News brief</h3><h2 id="1fcd294b-3f53-425f-9f20-4093e8623b59">Top headlines</h2><ul><li>Elon Musk <a target="_blank" rel="noopener" href="https://www.businessinsider.com/elon-musk-donald-trump-rally-butler-pennsylvania-assassination-attempt-2024-10">speaks at Donald Trump's rally</a> in Pennsylvania.</li><li>'Trump is going to win': Latino voters explain <a target="_blank" href="https://www.businessinsider.com/texas-latinos-shifting-right-trump-harris-gop-democrats-starr-county-2024-10">why they're moving to the right</a>.</li><li>Kamala Harris' tax plan for small businesses sounds like it will cost a lot of money. <a target="_blank" href="https://www.businessinsider.com/harris-tax-deduction-plan-small-business-startup-cost-2024-10">It won't</a>.</li><li>Jamie Dimon: <a target="_blank" href="https://www.businessinsider.com/jamie-dimon-denies-donald-trump-claim-endorse-2024-10">No, I haven't endorsed Donald Trump</a>.</li></ul><h2 id="8120060b-ae66-48dc-b149-f0489a30ffa2">3 things in markets</h2><div type="image" title="divorced elderly couple collaged with money and scribbles" height="900" width="1200" msid="114018835" hostid="261" sizebytes="221900"></div><ol><li>A major curveball in retirement preparedness. Divorce can derail the best-laid retirement plans, particularly for baby boomers (especially older women). <a target="_blank" href="https://www.businessinsider.com/divorced-boomers-lower-retirement-savings-401ks-social-security-income-2024-10">An analysis by BI shows</a> divorcees often have lower incomes and savings than married people.</li><li>The future of fintech. More than two dozen VCs nominated <a target="_blank" rel="noopener" href="https://www.businessinsider.com/49-most-promising-fintech-startups-according-top-vc-investors-2024">49 fintechs they believe are on the rise</a>. The startups, which haven't raised beyond a Series C, are focused on everything from AI (of course) to disrupting the insurance and healthcare industries.</li><li>More bad news for Trump Media. The No. 2 executive at former President Donald Trump's social media company resigned last week, with one report alleging his exit is tied to a whistleblower complaint. That follows a major shareholder selling their stake. <a target="_blank" href="https://www.businessinsider.com/donald-trump-truth-social-resignation-whistleblower-propublica-2024-10">But don't expect shares to crater</a>.</li></ol><h2 id="f4b54806-7f81-450c-ba32-92560d4fae9b">3 things in tech</h2><div type="image" title="Shopping bags with the Amazon logo in front of an orange grid background" height="1000" width="2000" msid="114018840" hostid="261" sizebytes="82008"></div><ol><li>Amazon Prime Day may look a little different this year. In addition to the usual Prime Day gadgets, like TVs and Airpods, Amazon is dishing out deals on tents, pocket knives, and chainsaws. It's a way for Amazon to market those items, typically sold at steep end-of-season discounts, as <a target="_blank" rel="noopener" href="https://www.businessinsider.com/amazon-october-prime-day-sale-includes-unusual-holiday-items-2024-10">early holiday deals</a>.</li><li>Microsoft told customers it lost log data for key security products. According to an update viewed by BI, <a target="_blank" href="https://www.businessinsider.com/microsoft-tells-customers-it-lost-log-data-key-security-products-2024-10">a software bug caused inconsistent collection of log data</a> for several important cloud services. Affected products included Microsoft Entra and Sentinel, though there's no evidence of cyberattacks stemming from the incident.</li><li>Hard times a-falling on the influencer middle class. Marketers are turning away from the small-time creators and micro influencers in favor of big stars and celebrities, a new survey found. It's a tough draw for those with less than 500,000 followers; the survey found more and <a target="_blank" href="https://www.businessinsider.com/micro-influencer-campaigns-decline-marketers-turn-to-big-stars-2024-10">more deals are going to those with audiences of millions</a>.</li></ol><h2 id="9260fa45-d397-4b3c-b4f8-4bb193976216">3 things in business</h2><div type="image" title="A man sits at a bar while being surrounded by dogs." height="1000" width="2000" msid="114018845" hostid="261" sizebytes="76756"></div><ol><li>It's not just you. Dogs are everywhere. Fewer adults may be having children, but that's not the case for pet ownership. Americans are spending more time and money on their "fur babies" — and public spaces are becoming more welcome to dogs. <a target="_blank" href="https://www.businessinsider.com/rise-of-dogs-and-childless-adults-shaping-real-estate-urban-amenities-2024-10">It might be the new normal</a>.</li><li>Starboard Value has its next target: pharma giant Pfizer. The activist investor has informed Pfizer that it has <a target="_blank" rel="noopener" href="https://www.businessinsider.com/starboard-activist-significant-stake-in-drugmaker-pfizer-2024-10">taken a significant stake in the drugmaker</a>, people familiar with the matter told BI. It comes after Pfizer's stock dropped significantly since it reached record highs in 2021 during the rollout of its COVID-19 vaccine.</li><li>The great stuff transfer. Baby boomers are starting to pass their wealth to younger generations, but it doesn't end there. They're also handing down their decades-old collection of prized possessions and <a target="_blank" href="https://www.businessinsider.com/millennial-gen-x-boomer-inheritance-stuff-house-collectibles-2024-10">leaving Gen Xers, millennials, and Gen Zers to deal with the mess</a>.</li></ol><h2 id="1ad7b482-3f4b-44b4-81b6-a864aa386478">In other news</h2><ul><li>Tim Tully taught himself to code at age 6 and still codes daily. Here's how computer science <a target="_blank" href="https://www.businessinsider.com/menlo-ventures-partner-tim-tully-invests-in-generative-ai-startups-2024-10">took him from startups to AI investing at Menlo Ventures</a>.</li><li>There are 3 signs that generative AI might be reaching peak market froth — <a target="_blank" href="https://www.businessinsider.com/generative-ai-market-froth-openai-cerebras-meta-2024-10">and it's not just OpenAI</a>.</li><li>China's stimulus won't fix its economy, <a target="_blank" href="https://www.businessinsider.com/china-stimulus-wont-fix-economy-xi-jinping-isnt-done-yet-2024-10">but Beijing isn't done yet</a>.</li><li>Why so many entry-level jobs <a target="_blank" rel="noopener" href="https://www.businessinsider.com/entry-level-jobs-tech-roles-require-years-of-experience-2024-10">aren't entry-level.</a></li></ul><h2 id="9f5d80ac-3466-429f-a50a-2ffbb70c65ff">What's happening today</h2><ul><li>Kamala Harris' "60 Minutes" interview airs on CBS at 8 p.m. EDT.</li><li>ASEAN summit continues in Vientiane, Laos.</li></ul>The Insider Today team: Dan DeFrancesco, deputy editor and anchor, in New York. Jordan Parker Erb, editor, in New York. Hallam Bullock, senior editor, in London. Grace Lett, editor, in Chicago. Amanda Yen, fellow, in New York. Milan Sehmbi, fellow, in London.

Earnings season kicks off after a blowout jobs report upended investors' hopes of another interest-rate cut

Incidence of stroke and related deaths are rising substantially around the world, with <keyword id="19900550" type="General" weightage="20" keywordseo="air-pollution" source="keywords">air pollution</keyword>, <keyword id="21334318" type="General" weightage="20" keywordseo="high-temperatures" source="keywords">high temperatures</keyword> and metabolic risk factors such as high blood pressure and physical inactivity, driving these increases, according to estimates published in The Lancet Neurology journal. Researchers found that the contribution of high temperatures to poor health and early death due to stroke has increased 72% since 1990 and is likely to continue increasing in the future, thereby highlighting how environmental factors can impact growing stroke burden. Further, for the first time, particulate matter or PM air pollution was found to have the same contribution as smoking towards causing a fatal form of brain bleed, according to the researchers forming the <keyword id="20691740" type="General" weightage="20" keywordseo="Global-Burden-of-Disease" source="keywords">Global Burden of Disease</keyword>, Injuries, and Risk Factors Study (GBD) group. The GBD study, the "largest and most comprehensive effort to quantify health loss across places and over time", is coordinated by the Institute for Health Metrics and Evaluation (IHME), University of Washington, US. Globally, the number of people experiencing a stroke for the first time rose to 119 lakh in 2021 -- up by 70% since 1990 -- while deaths related to stroke rose to 73 lakh, which was up by 44% since 1990, making the neurological condition the third leading cause of death after ischaemic heart disease (short supply of blood to heart) and COVID-19. They added that over three-fourth of those affected by strokes live in low- and middle-income countries. According to lead author Valery L. Feigin from Auckland University of Technology, New Zealand, the rapid growth in the number of people affected by stroke strongly suggested that <keyword id="23228151" type="General" weightage="20" keywordseo="stroke-prevention" source="keywords">stroke prevention</keyword> strategies currently used are not sufficiently effective. "New, proven effective population-wide and motivational individual prevention strategies that could be applied to all people at risk of having a stroke, regardless of the level of risk, as recommended in the recent Lancet Neurology Commission on Stroke should be implemented across the globe urgently," said Feigin. The researchers also estimated that stroke-related liabilities attributable to 23 modifiable risk factors, including air pollution, excess body weight, high blood pressure, smoking and physical inactivity, increased from 100 million years of healthy life lost in 1990 to 135 million in 2021. These risk factors are present in huge numbers in Eastern Europe, Asia and sub-Saharan Africa, they said. The authors also acknowledged substantial progress made in reducing the global stroke burden from risk factors linked to poor diet, air pollution and smoking. Poor health resulting from diets high in processed meat and low in vegetables declined by 40 % and 30%, respectively, while that due to PM air pollution and smoking fell by 20 % and 13%, respectively, they found. The results suggested that strategies for reducing exposure to these risk factors over the past three decades such as clean air zones and public smoking bans have been successful, the authors said. They called for implementing and monitoring the evidence-based recommendations set out in the 2023 World Stroke Organization-Lancet Neurology Commission on stroke for drastically reducing the global burden of stroke in the years to come and improving brain health and overall well-being of millions of people around the world. The recommendations include stroke surveillance programmes that monitor indicators of stroke such as incidence, recurrence, death rates and risk factors in a country, and care and rehabilitation services for people affected by stroke.

You Searched For "covid 19 case fatality rate" and got 10 results

Tuberculosis dethrones COVID-19 as world’s top infectious killer again; Half of all new cases from India, Indonesia

Ankush Banerjee

More transmissible, higher fatality rate: India records first case of fast-spreading Mpox strain Clade 1B in Kerala man

BI India Bureau

How did we manage to deal with COVID-19 so quickly, but the common cold still remains a persisting problem?

Ankush Banerjee

Humans are spilling the COVID-19 virus back into wildlife! Study finds widespread infection in backyard animals

Kunal Kambli

India reports 3,016 new Covid-19 cases, daily positive rate at 2.7%

ANI

Scientists warn of bird flu pandemic that could be '100 times worse' than COVID after rare human case found in US

ANI

Should you be worried about the potential side-effects of the Covishield vaccine?

Ankush Banerjee

An emergency rate cut in the next week is looking more likely

Jennifer Sor

Earnings season kicks off after a blowout jobs report upended investors' hopes of another interest-rate cut

Dan DeFrancesco

Stroke cases increasing globally, air pollution, high temperatures driving numbers, notes Lancet Study

PTI

Popular Keywords

Buying Guides